慢性乙型肝炎合并脂肪性肝病患者的全因与病因特异性死亡率
在台湾大学医院回顾性纳入2006至2021年8718例慢性乙型肝炎合并脂肪性肝病患者,中位随访9.1年。代谢功能障碍相关脂肪性肝病组全因死亡风险高于非该组(调整后HR 1.79,95%CI 1.24-2.58,p=0.002),累积代谢危险因素呈剂量依赖性升高全因、肝相关和心血管死亡风险。倾向评分匹配后脂肪性肝病患者死亡风险低于无脂肪性肝病患者(HR 0.62,95%CI 0.53-0.74,p<0.001)。
要点
- 慢性乙型肝炎合并脂肪性肝病患者中,代谢功能障碍相关脂肪性肝病组全因死亡风险升高(调整后HR 1.79)。
- 累积代谢危险因素呈剂量依赖性升高全因、肝相关和心血管死亡风险(均p<0.05)。
- 随访中新发糖尿病、高血压和显著体重增加进一步升高全因和肝相关死亡风险(均p<0.05)。
核心结论
- 在慢性乙型肝炎合并脂肪性肝病患者中,代谢负担呈剂量依赖性升高全因、肝相关和心血管死亡风险。
- 脂肪性肝病患者死亡风险低于无脂肪性肝病患者(倾向评分匹配后HR 0.62,95%CI 0.53-0.74,p<0.001)。
- 识别这些代谢功能障碍对日常护理中的风险分层至关重要。
研究设计与样本
- 回顾性连续纳入2006至2021年台湾大学医院慢性乙型肝炎合并脂肪性肝病患者共8718例。
- 代谢功能障碍相关脂肪性肝病根据心血管代谢危险因素的存在定义,分为代谢功能障碍相关脂肪性肝病组(n=6562)和非该组(n=2156)。
- 比较全因和病因特异性死亡的累积发生率,中位随访9.1年。
主要发现
- 代谢功能障碍相关脂肪性肝病组较非该组年龄更大,HBeAg阳性比例和HBV DNA水平更低。
- 代谢功能障碍相关脂肪性肝病组全因死亡风险高于非该组(调整后HR 1.79,95%CI 1.24-2.58,p=0.002)。
- 累积代谢危险因素呈剂量依赖性升高全因、肝相关和心血管死亡风险(均p<0.05)。
- 随访期间新发糖尿病、高血压和显著体重增加进一步升高全因和肝相关死亡风险(均p<0.05)。
- 倾向评分匹配后,脂肪性肝病患者死亡风险低于无脂肪性肝病患者(HR 0.62,95%CI 0.53-0.74,p<0.001)。
临床怎么用
- 在慢性乙型肝炎合并脂肪性肝病患者的日常护理中,识别代谢功能障碍对风险分层至关重要。
- 常规筛查和监测代谢功能障碍是慢性乙型肝炎患者日常护理的关键要素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Steatotic liver disease (SLD) is prevalent among patients with chronic hepatitis B (CHB). However, the effects of metabolic dysfunction-associated SLD (MASLD) on the long-term survival of such patients remain unknown. Accordingly, this study investigated the mortality risks in patients with CHB and concurrent SLD. METHODS: Consecutive patients with CHB and concurrent SLD were retrospectively recruited at National Taiwan University Hospital. MASLD was defined by the presence of cardiometabolic risk factors. The cumulative incidences of all-cause and cause-specific mortality were compared. RESULTS: A total of 8,718 patients with CHB and concurrent SLD were included from 2006 to 2021. At baseline, the MASLD group (n = 6,562) was older and had a lower proportion of HBeAg positivity and lower HBV DNA levels compared with the non-MASLD group (n = 2,156). After a median follow-up period of 9.1 years, the MASLD group exhibited a higher risk of all-cause mortality compared with the non-MASLD group (adjusted hazard ratio 1.79, 95% CI 1.24-2.58, p = 0.002). Furthermore, cumulative cardiometabolic risk factors dose-dependently elevated the risks of all-cause, liver-related, and cardiovascular mortality (all p <0.05). During the follow-up period, new-onset diabetes mellitus, hypertension, and significant weight gain further increased the risks of all-cause and liver-related mortality (all p <0.05). However, patients with SLD had a lower mortality risk than those without SLD after propensity score matching (hazard ratio 0.62, 95% CI 0.53-0.74, p <0.001). CONCLUSIONS: Among patients with CHB and SLD, metabolic burden dose-dependently increases all-cause, liver-related, and cardiovascular mortality risks. Patients with SLD have a lower mortality risk than those without SLD. Identifying these metabolic dysfunctions is crucial for stratifying the level of risk in daily care. IMPACT AND IMPLICATIONS: Concurrent steatotic liver disease (SLD) is prevalent among patients with chronic hepatitis B (CHB); however, the effects of the associated cardiometabolic risk factors on all-cause and cause-specific mortality remain unknown. This study demonstrated that cumulative metabolic burden dose-dependently increased the risks of all-cause, liver-related, and cardiovascular mortality in patients with CHB and SLD. Moreover, new-onset diabetes mellitus, hypertension, and weight gain during the follow-up period further exacerbated these risks. However, patients with SLD had a lower risk of mortality than those without SLD. Thus, routine screening and monitoring of metabolic dysfunctions constitute a key element of daily care for patients with CHB.
引用
- Huang SC, Su TH, Tseng TC, et al. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol. 2024. PMID: 39675434. doi:10.1016/j.jhep.2024.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。